{"id":444,"date":"2021-12-25T12:14:01","date_gmt":"2021-12-25T04:14:01","guid":{"rendered":"http:\/\/nugene.com.cn\/en\/?p=444"},"modified":"2021-12-25T12:14:04","modified_gmt":"2021-12-25T04:14:04","slug":"the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov","status":"publish","type":"post","link":"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/","title":{"rendered":"The Lancet published the Phase III clinical trial results on the safety and efficacy of \u201cAd5-nCoV\u201d"},"content":{"rendered":"\n<p class=\"has-drop-cap\">Dec 23, 2021\uff0cCanSino Biologics Inc. announced that <a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(21)02753-7\/fulltext#seccestitle170\">The Lancet<\/a>&nbsp;published its Phase III clinical trial results on the safety and efficacy of its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (\u201cAd5-nCoV\u201d, trade name: Convidecia\u2122). The publication of the analysis showed that a single dose of Convidecia\u2122&nbsp;is efficacious and safe&nbsp;with an efficacy of 96.0% in preventing severe COVID-19 disease and an&nbsp;overall efficacy of&nbsp;63.7%&nbsp;14 days post-vaccination for&nbsp;healthy adults&nbsp;aged 18 and above, without any reported vaccine-related serious adverse events.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-gallery columns-1 is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex\"><ul class=\"blocks-gallery-grid\"><li class=\"blocks-gallery-item\"><figure><img loading=\"lazy\" decoding=\"async\" width=\"798\" height=\"431\" src=\"http:\/\/nugene.com.cn\/en\/wp-content\/uploads\/2021\/12\/image.png\" alt=\"\" data-id=\"463\" class=\"wp-image-463\" srcset=\"https:\/\/nugene.com.cn\/en\/wp-content\/uploads\/2021\/12\/image.png 798w, https:\/\/nugene.com.cn\/en\/wp-content\/uploads\/2021\/12\/image-300x162.png 300w, https:\/\/nugene.com.cn\/en\/wp-content\/uploads\/2021\/12\/image-768x415.png 768w\" sizes=\"auto, (max-width: 798px) 100vw, 798px\" \/><figcaption class=\"blocks-gallery-item__caption\">picture from the web<\/figcaption><\/figure><\/li><\/ul><\/figure>\n\n\n\n<p>\u201cWe are thrilled to have our Phase III trial results fully disclosed and published in The Lancet, one of the world\u2019s most prestigious peer-reviewed medical journals. This represents another milestone and provides further evidence of the strong protection provided by our single-dose vaccine, which is now approved in at least 10 markets across multiple continents. CanSinoBIO remains committed to our mission of providing affordable, timely and mass immune protection to the global population, and will continue to collaborate with partners in the public and private sectors to improve vaccine access and have more people benefit from our technology breakthroughs,\u201d said Dr. Xuefeng YU, Chairman and Chief Executive Officer of CanSinoBIO.<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dec 23, 2021\uff0cCanSino Biologics Inc. announced that The Lancet&nbsp;published its Phase III clinical trial results on the safety and efficacy of its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (\u201cAd5-nCoV\u201d, trade name: Convidecia\u2122). The publication of the analysis showed that a single dose of Convidecia\u2122&nbsp;is efficacious and safe&nbsp;with an efficacy of 96.0% in preventing &hellip;<\/p>\n<p class=\"read-more\"> <a class=\"\" href=\"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/\"> <span class=\"screen-reader-text\">The Lancet published the Phase III clinical trial results on the safety and efficacy of \u201cAd5-nCoV\u201d<\/span> Read More &raquo;<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","footnotes":""},"categories":[7,6,9],"tags":[29,31,30],"class_list":["post-444","post","type-post","status-publish","format-standard","hentry","category-china","category-news","category-rd","tag-cansino-biologics","tag-coronavirus-vaccine","tag-covid-19"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The Lancet published the Phase III clinical trial results on the safety and efficacy of \u201cAd5-nCoV\u201d - Nucleic acid Building Block<\/title>\n<meta name=\"description\" content=\"Nucleic acid Building Block The Lancet published the Phase III clinical trial results on the safety and efficacy of \u201cAd5-nCoV\u201d\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Lancet published the Phase III clinical trial results on the safety and efficacy of \u201cAd5-nCoV\u201d - Nucleic acid Building Block\" \/>\n<meta property=\"og:description\" content=\"Nucleic acid Building Block The Lancet published the Phase III clinical trial results on the safety and efficacy of \u201cAd5-nCoV\u201d\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/\" \/>\n<meta property=\"og:site_name\" content=\"Nucleic acid Building Block\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-25T04:14:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-25T04:14:04+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/nugene.com.cn\/en\/wp-content\/uploads\/2021\/12\/image.png\" \/>\n<meta name=\"author\" content=\"NuGene_news\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AndyLu_Pharma\" \/>\n<meta name=\"twitter:site\" content=\"@AndyLu_Pharma\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"NuGene_news\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/\"},\"author\":{\"name\":\"NuGene_news\",\"@id\":\"http:\/\/nugene.com.cn\/en\/#\/schema\/person\/7f01d2120af2894116ca8b8d025aafe4\"},\"headline\":\"The Lancet published the Phase III clinical trial results on the safety and efficacy of \u201cAd5-nCoV\u201d\",\"datePublished\":\"2021-12-25T04:14:01+00:00\",\"dateModified\":\"2021-12-25T04:14:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/\"},\"wordCount\":219,\"publisher\":{\"@id\":\"http:\/\/nugene.com.cn\/en\/#organization\"},\"keywords\":[\"Cansino biologics\",\"Coronavirus Vaccine\",\"COVID-19\"],\"articleSection\":[\"China\",\"News\",\"R&amp;D\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/\",\"url\":\"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/\",\"name\":\"The Lancet published the Phase III clinical trial results on the safety and efficacy of \u201cAd5-nCoV\u201d - Nucleic acid Building Block\",\"isPartOf\":{\"@id\":\"http:\/\/nugene.com.cn\/en\/#website\"},\"datePublished\":\"2021-12-25T04:14:01+00:00\",\"dateModified\":\"2021-12-25T04:14:04+00:00\",\"description\":\"Nucleic acid Building Block The Lancet published the Phase III clinical trial results on the safety and efficacy of \u201cAd5-nCoV\u201d\",\"breadcrumb\":{\"@id\":\"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9875\",\"item\":\"http:\/\/nugene.com.cn\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Lancet published the Phase III clinical trial results on the safety and efficacy of \u201cAd5-nCoV\u201d\"}]},{\"@type\":\"WebSite\",\"@id\":\"http:\/\/nugene.com.cn\/en\/#website\",\"url\":\"http:\/\/nugene.com.cn\/en\/\",\"name\":\"Nucleic acid Building Block\",\"description\":\"service@nugene.com.cn; Hangzhou, China\",\"publisher\":{\"@id\":\"http:\/\/nugene.com.cn\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\/\/nugene.com.cn\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"http:\/\/nugene.com.cn\/en\/#organization\",\"name\":\"Nugene Biopharm Science\",\"url\":\"http:\/\/nugene.com.cn\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/nugene.com.cn\/en\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/nugene.com.cn\/en\/wp-content\/uploads\/2021\/08\/logo-2.png\",\"contentUrl\":\"http:\/\/nugene.com.cn\/en\/wp-content\/uploads\/2021\/08\/logo-2.png\",\"width\":180,\"height\":60,\"caption\":\"Nugene Biopharm Science\"},\"image\":{\"@id\":\"http:\/\/nugene.com.cn\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/twitter.com\/AndyLu_Pharma\",\"https:\/\/www.linkedin.com\/company\/nugene\/?viewAsMember=true\"]},{\"@type\":\"Person\",\"@id\":\"http:\/\/nugene.com.cn\/en\/#\/schema\/person\/7f01d2120af2894116ca8b8d025aafe4\",\"name\":\"NuGene_news\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/nugene.com.cn\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bee8263273a0f4551ff1cd73990569f65148b8c24aacd5ac6b61f310d82ccf64?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bee8263273a0f4551ff1cd73990569f65148b8c24aacd5ac6b61f310d82ccf64?s=96&d=mm&r=g\",\"caption\":\"NuGene_news\"},\"url\":\"https:\/\/nugene.com.cn\/en\/index.php\/author\/nugene02\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Lancet published the Phase III clinical trial results on the safety and efficacy of \u201cAd5-nCoV\u201d - Nucleic acid Building Block","description":"Nucleic acid Building Block The Lancet published the Phase III clinical trial results on the safety and efficacy of \u201cAd5-nCoV\u201d","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/","og_locale":"en_US","og_type":"article","og_title":"The Lancet published the Phase III clinical trial results on the safety and efficacy of \u201cAd5-nCoV\u201d - Nucleic acid Building Block","og_description":"Nucleic acid Building Block The Lancet published the Phase III clinical trial results on the safety and efficacy of \u201cAd5-nCoV\u201d","og_url":"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/","og_site_name":"Nucleic acid Building Block","article_published_time":"2021-12-25T04:14:01+00:00","article_modified_time":"2021-12-25T04:14:04+00:00","og_image":[{"url":"http:\/\/nugene.com.cn\/en\/wp-content\/uploads\/2021\/12\/image.png"}],"author":"NuGene_news","twitter_card":"summary_large_image","twitter_creator":"@AndyLu_Pharma","twitter_site":"@AndyLu_Pharma","twitter_misc":{"Written by":"NuGene_news","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/#article","isPartOf":{"@id":"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/"},"author":{"name":"NuGene_news","@id":"http:\/\/nugene.com.cn\/en\/#\/schema\/person\/7f01d2120af2894116ca8b8d025aafe4"},"headline":"The Lancet published the Phase III clinical trial results on the safety and efficacy of \u201cAd5-nCoV\u201d","datePublished":"2021-12-25T04:14:01+00:00","dateModified":"2021-12-25T04:14:04+00:00","mainEntityOfPage":{"@id":"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/"},"wordCount":219,"publisher":{"@id":"http:\/\/nugene.com.cn\/en\/#organization"},"keywords":["Cansino biologics","Coronavirus Vaccine","COVID-19"],"articleSection":["China","News","R&amp;D"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/","url":"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/","name":"The Lancet published the Phase III clinical trial results on the safety and efficacy of \u201cAd5-nCoV\u201d - Nucleic acid Building Block","isPartOf":{"@id":"http:\/\/nugene.com.cn\/en\/#website"},"datePublished":"2021-12-25T04:14:01+00:00","dateModified":"2021-12-25T04:14:04+00:00","description":"Nucleic acid Building Block The Lancet published the Phase III clinical trial results on the safety and efficacy of \u201cAd5-nCoV\u201d","breadcrumb":{"@id":"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nugene.com.cn\/en\/index.php\/the-lancet-published-the-phase-iii-clinical-trial-results-on-the-safety-and-efficacy-of-ad5-ncov\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9875","item":"http:\/\/nugene.com.cn\/en\/"},{"@type":"ListItem","position":2,"name":"The Lancet published the Phase III clinical trial results on the safety and efficacy of \u201cAd5-nCoV\u201d"}]},{"@type":"WebSite","@id":"http:\/\/nugene.com.cn\/en\/#website","url":"http:\/\/nugene.com.cn\/en\/","name":"Nucleic acid Building Block","description":"service@nugene.com.cn; Hangzhou, China","publisher":{"@id":"http:\/\/nugene.com.cn\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/nugene.com.cn\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"http:\/\/nugene.com.cn\/en\/#organization","name":"Nugene Biopharm Science","url":"http:\/\/nugene.com.cn\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/nugene.com.cn\/en\/#\/schema\/logo\/image\/","url":"http:\/\/nugene.com.cn\/en\/wp-content\/uploads\/2021\/08\/logo-2.png","contentUrl":"http:\/\/nugene.com.cn\/en\/wp-content\/uploads\/2021\/08\/logo-2.png","width":180,"height":60,"caption":"Nugene Biopharm Science"},"image":{"@id":"http:\/\/nugene.com.cn\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/twitter.com\/AndyLu_Pharma","https:\/\/www.linkedin.com\/company\/nugene\/?viewAsMember=true"]},{"@type":"Person","@id":"http:\/\/nugene.com.cn\/en\/#\/schema\/person\/7f01d2120af2894116ca8b8d025aafe4","name":"NuGene_news","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/nugene.com.cn\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bee8263273a0f4551ff1cd73990569f65148b8c24aacd5ac6b61f310d82ccf64?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bee8263273a0f4551ff1cd73990569f65148b8c24aacd5ac6b61f310d82ccf64?s=96&d=mm&r=g","caption":"NuGene_news"},"url":"https:\/\/nugene.com.cn\/en\/index.php\/author\/nugene02\/"}]}},"_links":{"self":[{"href":"https:\/\/nugene.com.cn\/en\/index.php\/wp-json\/wp\/v2\/posts\/444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nugene.com.cn\/en\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nugene.com.cn\/en\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nugene.com.cn\/en\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/nugene.com.cn\/en\/index.php\/wp-json\/wp\/v2\/comments?post=444"}],"version-history":[{"count":5,"href":"https:\/\/nugene.com.cn\/en\/index.php\/wp-json\/wp\/v2\/posts\/444\/revisions"}],"predecessor-version":[{"id":467,"href":"https:\/\/nugene.com.cn\/en\/index.php\/wp-json\/wp\/v2\/posts\/444\/revisions\/467"}],"wp:attachment":[{"href":"https:\/\/nugene.com.cn\/en\/index.php\/wp-json\/wp\/v2\/media?parent=444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nugene.com.cn\/en\/index.php\/wp-json\/wp\/v2\/categories?post=444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nugene.com.cn\/en\/index.php\/wp-json\/wp\/v2\/tags?post=444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}